United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
May 01, 2024 at 06:32 am EDT
Share
United Therapeutics Corporation reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 677.7 million compared to USD 506.9 million a year ago. Net income was USD 306.6 million compared to USD 240.9 million a year ago.
Basic earnings per share from continuing operations was USD 6.52 compared to USD 5.2 a year ago. Diluted earnings per share from continuing operations was USD 6.17 compared to USD 4.86 a year ago.
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
UNITED THERAPEUTICS CORPORATION 
